Immuron receives european patent on drug composition to treat clostridioides difficile associated disease

Melbourne, australia, jan. 17, 2023 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), an australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce that has been granted a european patent for compositions and methods for the treatment and/or prophylaxis of clostridioides difficile associated disease.
IMRN Ratings Summary
IMRN Quant Ranking